Federal Act
on Medicinal Products and Medical Devices
(Therapeutic Products Act, TPA)


Open article in different language:  DE  |  FR  |  IT
Art. 15 Marketing authorisation on the basis of a notification 59

1 The fol­low­ing may be placed on the mar­ket fol­low­ing no­ti­fic­a­tion to the Agency:

a.
com­ple­ment­ary medi­cines without in­dic­a­tions, the act­ive sub­stances of which are in­cluded in lists for spe­cif­ic ther­apy ap­proaches;
b.
oth­er medi­cin­al products or groups of medi­cin­al products for which, due to their low risk po­ten­tial, a sim­pli­fied mar­ket­ing au­thor­isa­tion proves to be dis­pro­por­tion­ate.

2 The Agency shall draw up the lists re­ferred to in para­graph 1 let­ter a. It shall de­term­ine the medi­cin­al products or groups of medi­cin­al products re­ferred to in para­graph 1 let­ter b and reg­u­late the no­ti­fic­a­tion pro­ced­ure.

59 Amended by No I of the FA of 18 March 2016, in force since 1 Jan. 2019 (AS 2017 2745, 2018 3575; BBl 2013 1).

Diese Seite ist durch reCAPTCHA geschützt und die Google Datenschutzrichtlinie und Nutzungsbedingungen gelten.

Feedback
Laden